Hepatocellular adenoma MRI: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 21: Line 21:
*After injection of a hepatocellular-specific contrast agent such as gadolinium benzyloxypropionictetraacetate (Gd-BOPTA) there is usually no substantial uptake.
*After injection of a hepatocellular-specific contrast agent such as gadolinium benzyloxypropionictetraacetate (Gd-BOPTA) there is usually no substantial uptake.
<Gallery>
<Gallery>
Axial_T1_out_of_phase_hepatic_adenoma.jpg|Selected images from liver MRI show a large, subtle T2 hyperintense, well defined rounded lesion in the liver which demonstrates homogenous signal loss on T1 opposed phase scans. Post contrast images, there is prompt arterial enhancement and lesional washout. Incidental lesion lateral to the main one is seen, best appreciated on the arterial phase.  
Axial_T1_out_of_phase_hepatic_adenoma.jpg|liver MRI show a large, subtle T2 hyperintense, well defined rounded lesion in the liver which demonstrates homogenous signal loss on T1 opposed phase scans.


Hepatic-adenoma-T2_fat_sat.jpg
Hepatic-adenoma-T2_fat_sat.jpg

Revision as of 20:39, 16 October 2015

Hepatocellular adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatocellular adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular adenoma MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular adenoma MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular adenoma MRI

CDC on Hepatocellular adenoma MRI

Hepatocellular adenoma MRI in the news

Blogs on Hepatocellular adenoma MRI

Directions to Hospitals Treating Hepatocellular adenoma

Risk calculators and risk factors for Hepatocellular adenoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

MRI

  • On T1-weighted MR images, hepatocellular adenomas have been variously described as hyperintense, isointense, and hypointense lesions.
  • It has been reported that 47%–74% of hepatocellular adenomas are predominantly hyperintense relative to liver on T2-weighted images; this is due to prolonged T2 and is consistent with findings in other hepatic tumors.
  • Some lesions are hypointense and isointense on T2-weighted images.
  • Most lesions are heterogeneous, demonstrating a combination of hyper- and hypointensity on T2-weighted images relative to hemorrhage and necrosis.
  • Dynamic gadolinium-enhanced gradient-echo MR imaging, like dynamic CT, can be used to demonstrate early arterial enhancement that reflects the presence of subcapsular feeding vessels.
  • Adenomas usually do not show uptake of superparamagnetic iron oxide particles, resulting in decreased signal intensity on T2-weighted images.
  • After injection of a hepatocellular-specific contrast agent such as gadolinium benzyloxypropionictetraacetate (Gd-BOPTA) there is usually no substantial uptake.

References


Template:WikiDoc Sources